# EDGAR Filing Document

**Accession Number:** 0001807983
**File Stem:** 0000000000-23-001757
**Filing Date:** 2023-2
**Character Count:** 3314
**Document Hash:** c5649cb1bcfaff1b8e6831d6503084ec
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-23-001757.hdr.sgml**: 20230328

**ACCESSION NUMBER**: 0000000000-23-001757

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230222

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Medicenna Therapeutics Corp.
- **CENTRAL INDEX KEY:** 0001807983
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** Z4
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** UPLOAD

**BUSINESS ADDRESS:**
- **STREET 1:** 2 BLOOR ST W., 7TH FLOOR
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M4W 3E2
- **BUSINESS PHONE:** 416 648-5555

**MAIL ADDRESS:**
- **STREET 1:** 2 BLOOR ST W., 7TH FLOOR
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M4W 3E2
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001171843-23-001045

## Text-Extract

```

United States securities and exchange commission logo

                          February 22, 2023

       Elizabeth Williams
       Chief Financial Officer
       Medicenna Therapeutics Corp.
       28 Liberty Street
       New York, New York 10005

                                                        Re: Medicenna
Therapeutics Corp.
                                                            Registration
Statement on Form F-4
                                                            Filed February 17,
2023
                                                            File No. 333-269868

       Dear Elizabeth Williams:

              This is to advise you that we have not reviewed and will not
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Daniel
Crawford at 202-551-7767 with any questions.

                          Sincerely,

                          Division of Corporation Finance

                          Office of Life Sciences
       cc:                                              John Rudy, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

![img-0.jpeg](img-0.jpeg)

DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

February 22, 2023

Elizabeth Williams
Chief Financial Officer
Medicenna Therapeutics Corp.
28 Liberty Street
New York, New York 10005

**Re: Medicenna Therapeutics Corp.**
**Registration Statement on Form F-4**
**Filed February 17, 2023**
**File No. 333-269868**

Dear Elizabeth Williams:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Daniel Crawford at 202-551-7767 with any questions.

Sincerely,

Division of Corporation Finance
Office of Life Sciences

cc: John Rudy, Esq.